← Back to Search

Radiation

Radiotherapy for Prostate Cancer (MOB-RT Trial)

N/A

Recruiting

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologic diagnosis of prostate adenocarcinoma.

Age > 18 years.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 5-year follow-up

Awards & highlights

MOB-RT Trial Summary

This trial is testing a new cancer treatment for 100 patients with high-risk or node-positive prostate cancer. The treatment is a combination of radiotherapy and androgen deprivation therapy.

Who is the study for?

This trial is for men over 18 with high-risk localized prostate cancer or node-positive disease, who are generally in good health (ECOG status 0-1). They must not have had previous pelvic radiotherapy and should be free of metastatic disease as confirmed by imaging. Participants can give informed consent and may receive hormone therapy if their doctor thinks it's necessary.Check my eligibility

What is being tested?

The study is testing a specific type of radiation treatment called moderate hypofractionated boost to the prostate along with pelvic RT. It's designed for patients with serious forms of prostate cancer that hasn't spread beyond the pelvis. The trial will observe how well this intensified radiation approach works.See study design

What are the potential side effects?

Potential side effects from this type of radiation treatment could include urinary issues, bowel problems, fatigue, sexual dysfunction, and skin irritation around the treated area. Hormone therapy might also cause hot flashes, reduced sex drive, weight gain, and bone thinning.

MOB-RT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with prostate cancer.

Select...

I am older than 18 years.

Select...

My prostate cancer is considered high-risk based on its stage, grade, or PSA levels.

Select...

I can carry out all my daily activities without help.

MOB-RT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 5-year follow-up

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 5-year follow-up

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 5-year follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acute Grade >2 Gastrointestinal Toxicity

Secondary outcome measures

Graded criteria based on CTCAE version 5.0 for acute genitourinary toxicity and late genitourinary and gastrointestinal toxicity

Measure of oncologic outcomes

Measure of onocologic outcomes

+4 more

MOB-RT Trial Design

1Treatment groups

Experimental Treatment

Group I: Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation TherapyExperimental Treatment1 Intervention

External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,472 Previous Clinical Trials

484,904 Total Patients Enrolled

63 Trials studying Prostate Cancer

15,300 Patients Enrolled for Prostate Cancer

Media Library

$Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT05313815 — N/A$

$Prostate Cancer Research Study Groups: Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation Therapy$

$Prostate Cancer Clinical Trial 2023: Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) Highlights & Side Effects. Trial Name: NCT05313815 — N/A$

$Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05313815 — N/A$

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are currently engaged in this medical experiment?

"Indeed, clinicaltrials.gov data shows that this investigation is actively recruiting patients after its initial posting on July 18th 2022 and latest update on the same day. The research requires 100 participants to be recruited from 1 site."

Answered by AI

Is enrollment available in this clinical trial at the present time?

"According to the records on clinicaltrials.gov, this trial is open for enrolment. The study was initially made available on July 18th 2022 and has since been updated as of that same date."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

2022. "Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05313815.

All > Prostate Cancer